secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K/A
Filed at:   2025-08-08T23:59:59+00:00
Accession:  0001339970-25-000016
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01, 2.06
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma Phase 3 EFZO-FIT topline due mid-Sept; Q2 cash $83.2M, raised $30.7M ATM
--------------------------------------------------------------------------------

- Completed last patient visit in Phase 3 EFZO-FIT study for pulmonary sarcoidosis; topline results expected mid-September 2025.
- Interim Phase 2 data in SSc-ILD showed stable/improved mRSS in diffuse patients; no treatment-related serious adverse events.
- ATYR0101 advanced to IND candidate for pulmonary fibrosis; IND filing planned in H2 2026.
- Cash, equivalents and investments $83.2M at June 30, 2025; raised ~$30.7M in ATM offering after quarter-end.
- R&D expenses $15.4M, G&A $4.9M for Q2 2025; cash runway sufficient for one year after Phase 3 readout.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000133997025000016/0001339970-25-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000133997025000016/atyr-20250807.htm
  HTML page:      https://secwatch.observer/filing/0001339970-25-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer